Literature DB >> 32173696

Factors Associated with a Large Decline in Renal Function or Progression to Renal Insufficiency in Hospitalized Atrial Fibrillation Patients with Early-Stage CKD.

Lili Hu1,2, Qinmei Xiong1, Zhiqing Chen1, Linghua Fu1, Jinzhu Hu1, Qi Chen1, Weiping Tu2, Chengyun Xu2, Gaosi Xu2, Juxiang Li1, Kui Hong1,3.   

Abstract

Clinicians must consider renal function when administering anticoagulants for atrial fibrillation (AF). Determination of risk factors for renal function decline may enable identification of patients who require closer monitoring. We investigated the characteristics associated with renal function decline in patients with AF. The study cohort consisted of 631 AF patients who had at least one readmission during the follow-up period and stages 1-3 chronic kidney disease (CKD). The primary outcome measure was large renal function decline (≥30% decrease from baseline estimated glomerular filtration rate [eGFR]). The secondary outcome measure was a final eGFR < 60 mL/minute/1.73 m2 for those with a baseline eGFR above this level. The mean eGFR was 74.4 ± 18.5 mL/minute/1.73 m2, and the mean follow-up time was 30.2 ± 13.2 months. The primary outcome occurred in 155 patients (24.6%) and was associated with congestive heart failure (CHF), proteinuria, type of AF, and left atrial diameter (LAD) ≥ 45 mm. Among 478 patients with a baseline eGFR ≥ 60 mL/minute/1.73 m2, 137 (28.7%) progressed to renal failure (eGFR < 60 mL/minute/1.73 m2). A decreasing eGFR was associated with age ≥ 75 years, CHF, lower baseline eGFR, and LAD ≥ 45 mm. CHF, proteinuria, type of AF, and LAD ≥ 45 mm were associated with eGFR decline ≥ 30% in AF patients with CKD stages 1-3. Advanced age, CHF, lower baseline eGFR, and LAD ≥ 45 mm were associated with progression to renal insufficiency. These results should be considered when identifying patients who require more frequent monitoring of eGFR.

Entities:  

Keywords:  Left atrial diameter; eGFR decline

Year:  2020        PMID: 32173696     DOI: 10.1536/ihj.19-205

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  1 in total

1.  Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.

Authors:  Munveer Thind; Wojciech Zareba; Dan Atar; Harry J G M Crijns; Jun Zhu; Hui-Nam Pak; James Reiffel; Ulf Ludwigs; Mattias Wieloch; John Stewart; Peter Kowey
Journal:  Clin Cardiol       Date:  2022-01-12       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.